Lv1
70 积分 2025-09-24 加入
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia
3个月前
已完结
How I treat patients with AML using azacitidine and venetoclax
4个月前
已完结
How I treat patients with AML using azacitidine and venetoclax
4个月前
已完结
NPM1-mutated acute myeloid leukemia: from bench to bedside
5个月前
已完结
randomized trial comparing standard versus high-dose daunorubicin 419 induction in patients with acute myeloid leukemia
5个月前
已关闭
Advances in acute myeloid leukemia
5个月前
已完结
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial
6个月前
已完结
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
6个月前
已完结
皖公网安备34019202002308
